Danger signal, Toll-like receptor, and cancer immunotherapy

Kunzo Orita, Akira Gochi, Shuji Nakamura, Ryuichi Motoda

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The danger model is based on the premise that the innate immune system has evolved to recognize danger by activating antigen presenting cells (APCs) in inflammatory tissues, resulting in the induction of adaptive immunity in some cases. Recently, Toll-like receptor-signaling has been highlighted as a signal for growth, activation and maturation of APCs, and is considered to consist of the large part of danger signals. Old BRMs like BCG, OK-432 and PSK that have been used clinically for a long time should be reassessed as to whether or not they are ligands for Toll-like receptors, and reused in cancer immunotherapy, The relationship of Toll-like receptor-signaling and differentiation, activation and maturation of human dendritic cells has also been commented on in detail for future dendritic cell therapy against cancer.

Original languageEnglish
Pages (from-to)204-210
Number of pages7
JournalBiotherapy
Volume16
Issue number3
Publication statusPublished - 2002
Externally publishedYes

Fingerprint

Toll-Like Receptors
Immunotherapy
Antigen-Presenting Cells
Dendritic Cells
Picibanil
Neoplasms
Adaptive Immunity
Mycobacterium bovis
Cell- and Tissue-Based Therapy
Immune System
Ligands
Growth

Keywords

  • Cancer immunotherapy
  • Danger signal
  • Toll-like receptor

ASJC Scopus subject areas

  • Cancer Research
  • Immunology and Allergy

Cite this

Orita, K., Gochi, A., Nakamura, S., & Motoda, R. (2002). Danger signal, Toll-like receptor, and cancer immunotherapy. Biotherapy, 16(3), 204-210.

Danger signal, Toll-like receptor, and cancer immunotherapy. / Orita, Kunzo; Gochi, Akira; Nakamura, Shuji; Motoda, Ryuichi.

In: Biotherapy, Vol. 16, No. 3, 2002, p. 204-210.

Research output: Contribution to journalArticle

Orita, K, Gochi, A, Nakamura, S & Motoda, R 2002, 'Danger signal, Toll-like receptor, and cancer immunotherapy', Biotherapy, vol. 16, no. 3, pp. 204-210.
Orita K, Gochi A, Nakamura S, Motoda R. Danger signal, Toll-like receptor, and cancer immunotherapy. Biotherapy. 2002;16(3):204-210.
Orita, Kunzo ; Gochi, Akira ; Nakamura, Shuji ; Motoda, Ryuichi. / Danger signal, Toll-like receptor, and cancer immunotherapy. In: Biotherapy. 2002 ; Vol. 16, No. 3. pp. 204-210.
@article{4a24c0051ec94fe582daa61bc28a98d4,
title = "Danger signal, Toll-like receptor, and cancer immunotherapy",
abstract = "The danger model is based on the premise that the innate immune system has evolved to recognize danger by activating antigen presenting cells (APCs) in inflammatory tissues, resulting in the induction of adaptive immunity in some cases. Recently, Toll-like receptor-signaling has been highlighted as a signal for growth, activation and maturation of APCs, and is considered to consist of the large part of danger signals. Old BRMs like BCG, OK-432 and PSK that have been used clinically for a long time should be reassessed as to whether or not they are ligands for Toll-like receptors, and reused in cancer immunotherapy, The relationship of Toll-like receptor-signaling and differentiation, activation and maturation of human dendritic cells has also been commented on in detail for future dendritic cell therapy against cancer.",
keywords = "Cancer immunotherapy, Danger signal, Toll-like receptor",
author = "Kunzo Orita and Akira Gochi and Shuji Nakamura and Ryuichi Motoda",
year = "2002",
language = "English",
volume = "16",
pages = "204--210",
journal = "Biotherapy",
issn = "0914-2223",
publisher = "Japanese Society for Cancer Chemotherapy",
number = "3",

}

TY - JOUR

T1 - Danger signal, Toll-like receptor, and cancer immunotherapy

AU - Orita, Kunzo

AU - Gochi, Akira

AU - Nakamura, Shuji

AU - Motoda, Ryuichi

PY - 2002

Y1 - 2002

N2 - The danger model is based on the premise that the innate immune system has evolved to recognize danger by activating antigen presenting cells (APCs) in inflammatory tissues, resulting in the induction of adaptive immunity in some cases. Recently, Toll-like receptor-signaling has been highlighted as a signal for growth, activation and maturation of APCs, and is considered to consist of the large part of danger signals. Old BRMs like BCG, OK-432 and PSK that have been used clinically for a long time should be reassessed as to whether or not they are ligands for Toll-like receptors, and reused in cancer immunotherapy, The relationship of Toll-like receptor-signaling and differentiation, activation and maturation of human dendritic cells has also been commented on in detail for future dendritic cell therapy against cancer.

AB - The danger model is based on the premise that the innate immune system has evolved to recognize danger by activating antigen presenting cells (APCs) in inflammatory tissues, resulting in the induction of adaptive immunity in some cases. Recently, Toll-like receptor-signaling has been highlighted as a signal for growth, activation and maturation of APCs, and is considered to consist of the large part of danger signals. Old BRMs like BCG, OK-432 and PSK that have been used clinically for a long time should be reassessed as to whether or not they are ligands for Toll-like receptors, and reused in cancer immunotherapy, The relationship of Toll-like receptor-signaling and differentiation, activation and maturation of human dendritic cells has also been commented on in detail for future dendritic cell therapy against cancer.

KW - Cancer immunotherapy

KW - Danger signal

KW - Toll-like receptor

UR - http://www.scopus.com/inward/record.url?scp=0036291891&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036291891&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0036291891

VL - 16

SP - 204

EP - 210

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 3

ER -